Objective: We evaluated tumour volume changes in patients with lung cancer undergoing concurrent chemoradiotherapy using image-guided radiotherapy (RT). Methods: The kilovoltage image was obtained using CT on rail at every five fractions. The gross tumour volumes (GTVs), including the primary tumour and lymph nodes (LNs), were contoured to analyse the time and degree of tumour regression. Results: 46 patients [32, non-small-cell lung cancer (NSCLC), and 14, small-cell lung cancer (SCLC)] were included in this study. In total, 281 CT scans and 82 sites of GTVs were evaluated. Significant volume changes occurred in both the NSCLC and SCLC groups (p , 0.001 and 0.002), and the average GTV change compared with baseline was 49.85 6 3.65 [standard error (SE)]% and 65.95 6 4.60 (SE)% for the NSCLC and SCLC groups, respectively. A significant difference in the degree of volume reduction between the primary tumour and LNs was observed in only the NSCLC group (p , 0.0001) but not in the SCLC group (p 5 0.735). The greatest volume regression compared with the volume before the five fractions occurred between the 15 and 20 fractions in the NSCLC group and between the 5 and 10 fractions in the SCLC group. Conclusion: Both primary tumour and LNs were well defined using CT on rail. Significant volume changes occurred during RT, and there was a difference in volume reduction between the NSCLC and SCLC groups, regarding the degree and timing of the tumour reduction in the primary tumour and LNs. Advances in knowledge: NSCLC and SCLC groups showed differences in the degree and timing of volume reduction. The primary tumour and LNs in NSCLC regressed differently.
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Lung cancer is the most common cause of cancer mortality in the Republic of Korea, accounting for 22.2% all cancer deaths. Although the survival rate continues to increase, the prognosis remains poor with a 5-year relative survival rate of 20.7% in patients diagnosed from 2007 to 2011. 1 Multimodality treatment, including radiotherapy (RT), is a mainstay in the treatment of locally advanced non-smallcell lung cancer (NSCLC) and limited-stage small-cell lung cancer (SCLC) because it improves local control and overall survival. [2] [3] [4] [5] Several recent studies have shown that an increasing radiation dose resulted in the improvement of local control and overall survival. [6] [7] [8] [9] Currently, Phase III randomized studies are under way to determine the optimal dose and fractionation schedule. Radiation oesophagitis and pneumonitis are major complications that limit the potential for dose escalation. Changes in tumour volume, patients' weight, pulmonary atelectasis and pleural effusions were noted during RT and modification of the treatment plan may be required over the course of the treatment. Adaptive planning can reduce the radiation exposure of an organ at risk (such as normal lung and oesophagus) and may improve local control.
Several studies have reported that tumour shrinkage occurs during RT using the various image-guided RT modalities, such as electronic portal imaging, megavoltage (MV) and kilovoltage (KV) cone beam CT (CBCT) and MVCT at tomotherapy. [10] [11] [12] [13] [14] However, there are few studies reporting the tumour regression timing of both the primary tumour and lymph nodes (LNs) owing to the limited image quality for LN evaluation. In this study, we analysed the degree of tumour regression in the primary tumour and LNs for patients with lung cancer undergoing concurrent chemoradiotherapy using CT on rail to determine the appropriate timing for adaptive planning.
METHODS AND MATERIALS
The data collection, storage and analysis were all performed in compliance with the institutional review board at St Mary's Hospital, Seoul, Republic of Korea. Patients who were treated with concurrent chemoradiotherapy for lung cancer were evaluated with image-guided radiation therapy (IGRT) for tumour volume change and target localization during their course of RT. They were treated at St Mary's Hospital between June 2009 and June 2011.
Planning CT scans were obtained with a SOMATOM® Sensation Open CT simulator (Siemens, Forchheim, Germany) with a slice thickness of 3 mm, under free-breathing conditions. A second CT scan, four-dimensional (4D) CT, was obtained using an Anzai respiratory monitoring system (AZ-733 V; Anzai Medical Co. Ltd, Tokyo, Japan) for tumour motion assessment and internal target volume generation. The clinical target volume (CTV) included the gross tumour volume (GTV) with an additional uniform 5 mm expansion and high-risk, uninvolved mediastinal LNs as well as the ipsilateral hilar LNs. Each tumour's motion was assessed with a Leonardo system (Siemens, Forchheim, Germany). The planning target volume was generated by adding 5-to 10-mm margins to the CTV according to the respiratory motion in the superoinferior, anteroposterior and left-right directions. Patients were treated with the three-dimensional conformal technique using 6-or 10-MV photons. Patients were treated on a linear accelerator with CT on rail system (CTVision™; Siemens, Forchheim, Germany), providing a KV image. During the RT course, patients were scheduled to undergo KVCT every five fractions. For once-a-day treatment with 1.8-2.0 Gy per fraction, KVCT was obtained once a week, and for twice-a-day treatment with 1.5 Gy per fraction, KVCT was obtained twice a week.
The images were exported to the Pinnacle 3 treatment planning system (Philips Healthcare, Milpitas, CA). Contours were drawn at the baseline of the free-breathing simulation CT and then on KVCT at fractions 5, 10, 15, 20, 25, 30 and 35. Primary tumour volumes and the abnormally enlarged LNs were separately contoured if they were well defined on each CT image set. The abnormally enlarged LNs having high 18-fludeoxyglucose ( 18 F-FDG) uptake on positron emission tomography (PET) CT or confirmed pathologically were included in this evaluation. Contours were drawn by a single physician with the same mediastinal and lung window setting for each GTV.
We summarized the changes in the tumour volume using descriptive statistics. Absolute tumour volumes, as well as the percentage change from the initial volume and the previous volume, were recorded. Repeated-measures analysis of variance SCLC, small-cell lung cancer. a Concurrent chemoradiotherapy was performed in patients with limited distant metastasis; one patient had a single brain metastasis, which was grossly removed before radiation; one patient had a single rib metastasis, which regressed after primary chemotherapy; and one patient had neck lymph node metastasis, which was included in the radiation field. b One patient with extensive disease received radiotherapy after primary etoposide 1 cisplatin chemotherapy with consolidative aim.
was used to evaluate the change of tumour volume over time.
p-values ,0.05 were considered to be significant. Statistical analyses were performed using SAS® v. 9.1 (SAS Institute, Cary, NC).
RESULTS

Patient characteristics
46 patients, including 32 with NSCLC and 14 with SCLC, were evaluated for GTV regression. All of the patients received concurrent chemoradiotherapy. Their age, sex, stage, histology, treatment aim, chemotherapy regimen and radiation dose are listed in Table 1 . The histology of NSCLC was squamous cell carcinoma (53%), adenocarcinoma (40.6%), large cell carcinoma (3.1%) and sarcomatoid carcinoma (3.1%). Patients were treated with a radical aim (68.75%), post-operative aim (18.75%) and pre-operative aim (12.5%) for NSCLC and with a radical aim (92.9%) and consolidative aim (7.10%) for SCLC. Most patients with NSCLC were treated with 1.8-2.0 Gy daily fractions, while half of the patients with SCLC were treated with a twice-daily schedule of 1. Figure 1a shows the mean total GTVs measured at every five fractions. Significant volume changes occurred during RT (p , 0.0001). An average of the total GTV change compared with the baseline GTV (the volume of the initial total GTV contoured in simulation CT) was 49.85% 6 3.65% [standard error (SE)], shown in Figure 2 .
There was a difference in volume distribution between the primary tumour and the LN sites (p , 0.0001). Significant volume changes occurred during RT in both groups (p , 0.0001), but there was a difference in the pattern of decrease (p , 0.0001) between the two groups, as shown in ), respectively, at the end of RT. There were significant volume changes during RT (p 5 0.002) as shown in Figure 1c , and the average of the total GTV changes at the completion of treatment compared with the initial volumes measured at baseline (simulation CT) was 65.95% 6 4.60% (SE) (Figure 2) . In contrast to the NSCLC group, there was no difference in volume distribution between the primary tumour and the LNs (p 5 0.700) in SCLC. Both the primary tumour and the LN sites showed significant volume changes with time (p 5 0.002), but there was no significant difference in the pattern of decrease between the two groups (p 5 0.735), as presented in Table 2 and Figure 1d .
The greatest tumour volume regression
To identify the time point at which the greatest tumour volume regression occurs, the mean volume changes relative to the previous GTV (volume before the five fractions) were also evaluated. The greatest volume regression appeared between 15 and 20 fractions for NSCLC, reaching approximately a mean of 16.29% 6 2.96% (SE). The primary tumour showed the greatest tumour volume regression between 10 and 15 fractions with 20.07% 6 3.91% (SE), and the LNs showed the greatest tumour volume regression between 15 and 20 fractions with 16.56% 6 3.73% (SE). For SCLC, the greatest tumour volume regression occurred earlier than for NSCLC, between 5 and 10 fractions with an average of 23.18% 6 5.28% (SE): primary tumour, 5 and 10 fractions, 24.53% 6 9.05 (SE), and LN, 10 and 15 fractions, 26.5% 6 8.29% (SE) (Figure 3 ).
Initial tumour volume effect
To evaluate the difference in the magnitude of volume changes between large and small tumours, we divided the initial volumes of tumours into two groups: small and large, depending on the median value. Both the primary tumour and the LN group of NSCLC showed a significant difference in tumour volume between the initial large and small tumour volumes (p 5 0.004 and p , 0.0001, respectively). They regressed with treatment over time in a significant manner (p , 0.0001 and p , 0.0001, respectively). Notably, initial large tumour volumes resulted in a greater rate of regression than those of the smaller initial tumours in both the primary tumour and the LN group (p 5 0.002 and p , 0.0001, respectively). In the primary tumours in the SCLC group, there were no significant differences in the tumour volume (p 5 0.181), and the pattern of their regression between the initial large and small group (p 5 0.078). However, the tumour volume regressed with time in both initial large and small groups (p 5 0.036). The LNs of the SCLC group showed a similar pattern to the primary tumours (Table 3) .
DISCUSSION
In lung cancer, the regression of primary tumours and LNs is expected during the course of RT, but the degree of regression and appropriate timing of treatment plan modification have not been well established. Recently, several studies regarding tumour regression have been published with various IGRT modalities, but difficulties relating to the interpretation of the results exist owing to the small number of patients and heterogeneity in treatments.
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In our study, the largest volume regression compared with the previous GTV (before the 5 fractions), occurred between 15 and 20 fractions (Figure 2) , and the graph of volume regression showed a plateau after 20 fractions (Figure 1 ). Therefore, it may be appropriate to consider adapting the plan within the first 20 fractions of NSCLC. Lim et al 10 described the volumetric and positional changes of the primary tumour, using respiratory-correlated CBCT imaging during the course of radical RT to a dose $45 Gy with concurrent chemotherapy in NSCLC. There was a mean per cent decrease of 51.1% by the completion of treatment in 31 patients, which was comparable to our result of 49.85%. Furthermore, they found that greater rates of tumour volume regression occurred during the initial week, compared with those during the later phases of the treatment. A study by Woodford et al 11 evaluated GTV changes by using MVCT and concluded that adaptive planning is beneficial as long as the GTV decreases by .30% in 20 fractions.
It has been considered that SCLC is both chemosensitive and radiosensitive, but the tumour behaviour of SCLC during the radiation treatment is not well known. Recently, Yee et al 12 quantified tumour volume shrinkage in limited disease of SCLC cases undergoing concurrent chemoradiotherapy and conducted serial chest CT scans 3 times a week in 10 patients. Most of the tumour regression occurred during the first week of RT, and the tumours regressed up to 12.4%, relative to the pre-RT volume, by the completion of treatment. In our study, the greatest tumour volume regression of SCLC occurred between 5 and 10 fractions, and the mean GTV relative to the pre-RT volume was 34.05% at the end of treatment. Yee et al did not differentiate between the primary tumours and LNs, and included conglomerated tumour volumes. Their initial GTV was larger than ours, which may have influenced the degree of volume reduction. Some studies did not find significant tumour volume regression during RT. A study by Siker et al 13 suggested that a field reduction is not recommended during RT because a substantial volumetric decrease of the primary tumour did not occur in weekly MVCTs. However, some patients in that study were treated with a palliative aim or stereotactic radioablation.
Volume changes of the primary tumour in lung cancer are frequently described, but little is known about the volume F-FDG PET CT scan was obtained before RT and in the second week of RT, and the volume and positional change of both the primary tumour and LNs were evaluated. They suggested that repeated mediastinal imaging may be necessary during RT, because LN behaviour differs from that of the primary tumour. However, Bosmans et al 15 observed that changes in the nodal volume and motion tend to fall within the commonly applied margins and suggested that the repeated imaging of the nodes seems to be of limited value. There are difficulties in delineating the mediastinal LNs, using KV-and MV-CBCT or MVCT at tomotherapy. CT on rail uses the scatterreducing fan beam geometry; thus, it has an outstanding image quality for soft-tissue contrast, such as mediastinal structures. We are able to delineate the central primary tumour and mediastinal LNs, as well as peripheral primary tumour, using CT on rail. Owing to the volume dynamics of the primary tumour being different from that of the LNs in NSCLC, as shown in the present study, we suggest that adaptive planning should be considered separately for the primary tumour and mediastinal LNs.
This study showed the results regarding the initial volume effect in NSCLC and SCLC. In NSCLC, both the primary tumour and LNs showed that initially large tumours regressed more markedly than small tumours. Lim et al 10 found similar results that larger tumours had a greater rate of regression than did smaller tumours of the peripheral primary tumour in NSCLC. However, in the SCLC cases in our study, this difference did not occur between the initial large and small tumour of the primary tumour and LNs. This observation may be explained by the rapid proliferation capacities of SCLC in the primary tumour and LNs, compared with NSCLC.
The limitation of this study is that respiratory motion was not accounted for, because it is difficult to acquire 4D respiratory motion information, owing to the fast image acquisition of CT on rail. The acquisition of a whole lung volume can be completed within approximately 10 s.
CONCLUSION
Both the primary tumour and LNs were well defined using CT on rail. Significant volume changes occurred during RT, and the largest volume regression compared with previous GTV occurred between 15 and 20 fractions in the NSCLC group and 5 and 10 fractions in the SCLC group, undergoing concurrent chemoradiotherapy. In the NSCLC group, the difference in the pattern of volume regression of the primary tumour and LNs was observed, and the initial large tumour regressed more rapidly. These results would be useful for reducing the probability of complications and to improve the therapeutic ratio of patients with lung cancer.
